论文部分内容阅读
目的:探索吉非替尼治疗晚期难治性小细胞肺癌(SCLC)的有效性和安全性。方法:口服吉非替尼250～500mg/d,按照WHO标准严密观察患者的临床症状、体征、生活质量的客观疗效。结果:1例反复多药、多疗程化疗失败的SCLC患者,合并急性上腔静脉综合征(SVCS),经脱水、利尿、大剂量环磷酰胺冲击化疗无效,2次应用吉非替尼均取得病情缓解,临床症状、体征消失,生活质量明显提高,而胸部瘤灶稳定,未见明显毒副反应。结论:吉非替尼治疗晚期难治性SCLC可能有效,值得临床进一步研究和观察。
Objective: To explore the efficacy and safety of gefitinib in the treatment of advanced refractory small cell lung cancer (SCLC). Methods: Gefitinib orally 250 ~ 500mg / d, according to WHO standards closely observe the clinical symptoms, signs, quality of life of the objective effect. Results: One case of SCLC patients with repeated multi-drug and multi-course chemotherapy failed with acute superior vena cava syndrome (SVCS) was ineffective after dehydration, diuresis and high-dose cyclophosphamide chemotherapy. Gefitinib The disease was relieved, clinical symptoms and signs disappeared, and the quality of life improved obviously. However, the thoracic tumor was stable with no obvious side effects. Conclusion: Gefitinib may be effective in the treatment of refractory advanced SCLC. It is worth further clinical study and observation.